[{"id":"1291c05a-73ca-4383-81e9-657fbb9b90c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520791","created_at":"2021-01-29T07:10:38.182Z","updated_at":"2024-07-02T16:35:16.577Z","phase":"Phase 1","brief_title":"Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma","source_id_and_acronym":"NCT02520791","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MEDI-570"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 09/13/2016","start_date":" 09/13/2016","primary_txt":" Primary completion: 08/04/2023","primary_completion_date":" 08/04/2023","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-03-04"}]